Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

It is well established that alterations in phosphate metabolism have a profound effect on
hard and soft tissues of the oral cavity. The present-day clinical form of osteonecrosis of the …

Abstract Sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent deacetylase,
epigenetically regulates various cell metabolisms, including inflammation, tumorigenesis …

The decline in bone mass and bone strength and musculoskeletal problems associated with
aging constitute a major challenge for affected individuals and the healthcare system …

ABSTRACT Sirtuin 1 (Sirt1), a protein deacetylase, is a novel target for bone metabolism. To
investigate whether overexpression of Sirt1 in mandibular mesenchymal stem cells (M …

With an aging population and limited treatment options, osteoporosis currently represents a
significant public health challenge. Recent animal studies indicate that longevity-associated …

Osteonecrosis of the jaw (ONJ) is a rare but serious drug induced adverse event, mainly
associated with the use of antiresorptive medications, such as intravenous (IV) …

Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug
reaction. Our previous whole‐exome sequencing study found SIRT1 intronic region single …

Background Histone deacetylase 9 (HDAC9) is a member of the HDAC gene family that
plays essential roles in the organization of transcriptional regulation by catalyzing …